Research in
1970s on use
of low-dose
aspirin to prevent
blood clotting
in kidney dialysis
patients suggested
that aspirin
could also reduce
risk of heart
attack, stroke
and other conditions
in healthy people.
Currently investigates
cell responses
to chemical
signals as growth
hormones.
Dr. Majerus’
work has evolved
around intracellular
signaling pathways
involving inositol
phosphates and
mechanisms of
blood coagulation
and platelet
function, leading
to pathogenic
platelet aggregation
and thrombosis.
His major contribution
is the development
of low-dose
aspirin as an
antithrombotic
agent. In over
30 years on
the Washington
University faculty,
Dr. Majerus
has trained
numerous M.D.,
M.D./Ph.D. and
Ph.D. students,
both pre- and
post-doctoral,
who have gone
on to distinguished
careers in biomedical
research. He
is a member
of the National
Academy of Sciences,
Institute of
Medicine and
the American
Academy of Arts
and Sciences.
He has won numerous
awards for his
research, including
most recently
the 1998 Bristol-Myers
Squibb Award
for Distinguished
Achievement
in Cardiovascular/
Metabolic Research.
|
